The role of setting for ketamine abuse: clinical and preclinical evidence by De Luca, Maria Teresa et al.
DOI 10.1515/revneuro-2012-0078      Rev. Neurosci. 2012; 23(5-6): 769–780
 Maria Teresa  De Luca ,  Maria  Meringolo ,  Primavera Alessandra  Spagnolo and  Aldo  Badiani * 
 The role of setting for ketamine abuse: clinical 
and preclinical evidence 
 Abstract:  Drug abuse is often seen as a unitary phenom-
enon, partly as a result of the discovery over the past three 
decades of shared mechanisms of action for addictive 
substances. Yet the pattern of drug taking is often very 
different from drug to drug. This is particularly evident in 
the case of  ‘ club drugs ’ , such as ketamine. Although the 
number of ketamine abusers is relatively small in the gen-
eral population, it is quite substantial in some settings. In 
particular, ketamine abuse is almost exclusively limited 
to clubs and large music parties, which suggests a major 
role of context in modulating the reward effects of this 
drug. This review focuses on recent preclinical and clini-
cal findings, including previously unpublished data, that 
provide evidence that, even under controlled conditions, 
ketamine reward is a function of the setting of drug taking. 
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 Introduction 
 Ketamine (ketamine chlorhydrate; CI-581) was synthe-
sized by Calvin Stevens in 1962 at the Parke-Davis Labora-
tories in Michigan. The new drug was chemically related 
to phencyclidine (PCP) but presented clear advantages 
in terms of toxicity relative to the parent drug (Domino 
et   al., 1965). Recovery (the  ‘ emergence ’ period) from PCP-
induced anesthesia is, in fact, associated with unwanted 
side effects, including confusion, unpleasant dreams and 
hallucinations (Siegel, 1978). Although ketamine also pro-
duces an emergence syndrome in 15%–40% of subjects 
(Dillon et    al., 2001), its shorter half-life makes it more 
acceptable than PCP. Because of its relatively favorable 
safety profile, ketamine rapidly became an anesthetic of 
choice for the American army during the Vietnam War. 
The dissociative effects of ketamine (that is, its ability 
to induce a lack of responsive awareness to the environ-
ment) were particularly useful in the battlefield. Today, 
ketamine is still widely used as an anesthetic in devel-
oping countries and in remote rural areas of developed 
countries, such as Australia, because of the minimal 
equipment requirements for its administration. In addi-
tion, ketamine remains the most widely used anesthetic 
in veterinary medicine. 
 Ketamine ’ s role in pain management goes beyond its 
use as a general anesthetic. Ketamine also has analgesic 
properties, preventing pain  ‘ wind-up ’ [that is, the sensi-
tization of neurons in the posterior horns of the spinal 
cord to pain stimuli (Sunder et al., 2008; Morgan and 
Curran, 2011)], and at low doses (0.1 – 0.5    mg/kg/h) pro-
duces a local anesthetic effect that is particularly useful in 
neuropathic pain (Correll et al., 2004; Lynch et al., 2005; 
Morgan and Curran, 2011). Ketamine has also been used 
in intensive care for the management of prolonged epi-
leptic seizures (Fujikawa, 1995). Other potential medical 
uses of ketamine are currently under investigation. In par-
ticular, ketamine is being tested for the treatment of anti-
depressant-resistant mood disorders and for heroin and 
alcohol addiction (Krupitsky and Grinenko, 1997; Krystal, 
2007; Aroni et al., 2009; Li et   al., 2010; Vollenweider and 
Kometer, 2010). 
 Another interesting aspect of the pharmacology of 
ketamine concerns its psychotomimetic effects. Indeed, 
some effects of ketamine resemble the symptoms of acute 
psychosis (Adler et   al., 1999). This has triggered research 
aimed at increasing our understanding of schizophre-
nia and at developing new therapies (Adler et    al., 1999; 
Carpenter, 1999). The ketamine  ‘ model ’ of schizophrenia 
is still the pharmacological model with the greatest face 
validity (Morgan and Curran, 2011). 
 The present review is not concerned with the medical 
uses of ketamine, nor with the ketamine model of psycho-
sis, but centers exclusively on the recreational misuse of 
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ketamine. Ketamine is very popular with some people for 
its ability to produce hallucinations and an internal state 
similar to a trance. Indeed, ketamine is taken mainly in 
club settings, which indicates a major role of context in 
modulating the reward effects of this drug (Curran and 
Morgan, 2000; Joe Laidler, 2005; Degenhardt and Dunn, 
2008). Thus, the review will focus on the role of context in 
ketamine abuse and, in particular, on recent experimental 
work conducted in rodents and humans. 
 Mechanisms of action of ketamine 
 Ketamine, like PCP, binds the N-methyl-D-aspartate 
(NMDA)-receptor complex at a site located within the 
channel (PCP-binding site). The excitatory amino acids 
glutamate, aspartate, and glycine are the endogenous ago-
nists at the NMDA receptor. Activation of NMDA receptors 
results in the opening of the channel with increased trans-
membrane flux of Na  +  , K  +  and Ca  + +  , and the depolarization 
of the neuron. Ketamine and PCP act as non-competitive 
NMDA receptor antagonists at the NMDA receptor. 
 Commercially available ketamine is a racemic mixture 
of two enantiomers. The S-enantiomer is the more potent 
of the two, with an anesthetic potency approximately 
three to four times that of R-ketamine. This correlates to 
the higher binding affinity for the PCP-site of the NMDA 
receptor. The psychotropic effects of ketamine are mainly 
caused by the S-enantiomer, although sub-anesthetic 
doses of R-ketamine have been shown to induce a state 
of relaxation (Engelhardt, 1997; Vollenweider et   al., 2000). 
 The principal metabolite of ketamine, nor-ketamine, 
is pharmacologically active. Its binding affinity to the 
NMDA receptor and its anesthetic properties are approxi-
mately one-third of the parent compound, contributing 
significantly to the analgesic effect of ketamine (Shimoyama 
et    al., 1999). The plasma levels at which ketamine anal-
gesia is achieved are 0.15  μ g/ml following intramuscular 
administration and 0.04  μ g/ml after oral administration. 
This difference may be explained by the greater relative 
contribution of nor-ketamine after oral relative to intra-
muscular administration. 
 The anesthetic and analgesic effects of ketamine and 
PCP are not surprising given the role of NMDA receptors in 
the transmission of sensory inputs at the spinal, thalamic, 
limbic and cortical levels. Ketamine interferes not only 
with the perception of pain per se, but also with the emo-
tional response to pain and with the formation of pain-
related memories (Green and Johnson, 1990; Bergman, 
1999; Sprenger et    al., 2006). The analgesic effects of 
ketamine may depend, in part, on its agonist properties 
at mu-opioid receptors located at the spinal and supra-
spinal level (Fink and Ngai, 1982; Crisp et   al., 1991; Sarton 
et    al., 2001). Ketamine was also found to potentiate the 
activation of mu-opioid receptors by opioid agonists 
(Gupta et    al., 2011). Furthermore, ketamine has been 
shown to prevent the development of morphine tolerance 
(Gonzalez et   al., 1997) and suppress morphine withdrawal 
syndrome in experimental settings, probably by acting at 
the level of the nucleus accumbens (Ji et   al., 2004). 
 Other effects of ketamine may be due to its actions 
on the catecholaminergic systems, notably on dopamine 
(DA) transmission (White and Ryan, 1996; Smith et    al., 
1998; Vollenweider et    al., 2000). It has been shown that 
ketamine stereo-specifically increases DA efflux in the 
nucleus accumbens and in the prefrontal cortex by mobi-
lizing the DA storage pool to releasable sites (Hancock and 
Stamford, 1999). In addition, ketamine has been shown 
to block DA reuptake (Hancock and Stamford, 1999) and 
activate D2 receptors (Kapur and Seeman, 2002). These 
dopaminergic effects may be implicated in the eupho-
rigenic, addictive and psychotomimetic properties of 
ketamine. The initial ketamine-induced DA overflow in 
the prefrontal cortex undergoes tolerance after repeated 
administrations, whereas the increase in extracellular 
5-hydroxyindole acetic acid (a serotonin metabolite) levels 
undergoes sensitization. This suggests that the balance 
between dopamine and serotonin neurotransmission in 
the prefrontal cortex may change after repeated exposure 
to ketamine (Lindefors et    al., 1997). Ketamine also acts 
as an agonist at  α - and  β -adrenergic receptors (Bevan 
et    al., 1997). Finally, ketamine has been shown to act as 
an antagonist at central muscarinic receptors and as an 
agonist at  σ -receptors (Anis et    al., 1983; Izquierdo et    al., 
1995; Bergman, 1999). 
 The psychotropic effects of ketamine can be observed 
in the presence of plasma concentrations ranging from 
50 to 300 ng/ml and with regional brain concentrations 
higher than 500 ng/ml (Hartvig et   al., 1995; Bowdle et   al., 
1998; Oranje et   al., 2000). 
 Ketamine abuse 
 The non-medical use of ketamine dates from the late 
1960s, when the drug began spreading from the Parke-
Davis Laboratories in Michigan to other states, particularly 
Florida, where it was sold as a hallucinogen with names 
such as  ‘ mean green ’ and  ‘ rockmesc ’ (i.e.,  ‘ rock mesca-
line ’ ) (Jansen, 2004). Ketamine use remained relatively 
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rare in Europe until the 1990s, when it appeared on the 
 ‘ rave ’ scene as an adulterant to ecstasy (3,4-methylene-
dioxy- N -methylamphetamine; MDMA) tablets (Dalgarno 
and Shewan, 1996). Other street names of ketamine are 
 ‘ Special K ’ ,  ‘ Vitamin K ’ ,  ‘ K ’ ,  ‘ Kit-kat ’ ,  ‘ Keets ’ ,  ‘ super acid ’ , 
 ‘ cut valium ’ , and  ‘ jet ’ . 
 Users report that ketamine is easier to take than other 
hallucinogenic drugs such as LSD and that its hallucino-
genic effects are more manageable, owing to a predictable 
dose-response curve of effects and a relatively short half-
life (Dillon et   al., 2003; Wolff and Winstock, 2006). 
 Ketamine is highly lipophilic and can be taken through 
various routes of administration: intranasal (snorting), 
intramuscular, oral, intravenous, subcutaneous and inha-
latory (smoking). Snorting represents the most popular 
route of administration. Dosing devices for snorting keta-
mine are called  ‘ bullets ’ or  ‘ bumpers ’ (Chakraborty et al., 
2010). Ketamine is often snorted in combination with other 
drugs ( ‘ trail mix ’ ), such as methamphetamine, cocaine 
(the so-called  ‘ Calvin Klein ’ ), sildenafil citrate or heroin 
(Tellier, 2002). Other popular drug combinations are taken 
orally (e.g., ketamine and MDMA) or via smoking (keta-
mine and cannabis). 
 At low doses, ketamine induces distortion of time 
and place, hallucinations and bizarre dissociative effects. 
According to many users, the most appealing effects of 
ketamine are represented by  ‘ melting into the surround-
ings ’ ,  ‘ visual hallucinations ’ ,  ‘ out-of body experiences ’ , 
and  ‘ giggliness ’ (Stewart, 2001). At higher doses, ketamine 
induces more severe dissociation, commonly referred to as 
 ‘ K-hole ’ , with the users experiencing intense detachment 
to the point that their perception appears to be completely 
divorced from their previous reality. Some users enjoy the 
experience of a K-hole and describe themselves as  ‘ psy-
chonauts ’ (see below), whereas others strongly dislike the 
resulting decrease in sociability (Dillon et   al., 2001). 
 According to the 2012 Ketamine Critical Review 
Report by the Expert Committee on Drug Dependence 
of the World Health Organization (WHO), in developed 
countries, street ketamine comes from two main supply 
sources: hospitals and veterinary clinics on the one hand, 
and illegal import from developing countries on the 
other. In the past, hospitals and veterinary clinics repre-
sented the main source of ketamine. This sort of supply 
is the most appreciated by consumers, as quality control 
is guaranteed by the pharmaceutical industry. Increasing 
regulatory control has made it more and more difficult, 
but not impossible, to obtain medical ketamine. Pres-
ently, street ketamine is mostly obtained from countries 
where it is still easily available, mainly China and India 
(Jansen, 2004). 
 Geographical distribution of 
ketamine abuse 
 As indicated by the 2010 United Nations World Drug 
Report, ketamine abuse is a global phenomenon with large 
geographical variation. In Hong Kong, for example, keta-
mine is thought to be the single most abused illicit drug, 
coming mostly from mainland China. However, although 
China produces massive amounts of ketamine, reliable 
estimates for the prevalence of ketamine abuse are not 
available. As of today, five Chinese factories are officially 
licensed to produce ketamine, but there are reports of 
illicit production on an industrial scale. In 2009, Chinese 
authorities reported the seizure of two illicit laboratories 
producing 8.5 million tons of the immediate precursor of 
ketamine. 
 Despite the efforts of several research groups, little 
is known of the epidemiology of ketamine abuse in other 
countries (WHO Expert Committee on Drug Dependence, 
2012). Topp et al. (2004) describe the Australian Illicit Drug 
Reporting System (IDRS) and the feasibility of monitoring 
market trends for  ‘ party drugs ’ . The trial demonstrated 
that the system can successfully monitor the market for 
widely used drugs, such as ecstasy, whereas it is much 
less sensitive in monitoring the markets for drugs that are 
used by small proportions of the total population, such as 
ketamine and other  ‘ club drugs ’ . 
 In the USA, according to an official 2009 NIDA publi-
cation, an estimated 1% – 2% of 10th – 12th graders reported 
having used ketamine (Johnston et   al., 2009). More uncer-
tain are the numbers for Europe. Reports of widespread 
recreational use of ketamine in the UK began to appear in 
the literature from the early 1990s (Jansen, 1993; Dalgarno 
and Shewan, 1996). Estimates suggest an increase in the 
number of ketamine users from approximately 85,000 in 
2006/2007 to approximately 113,000 in 2008/2009 (Hoare, 
2009). Additional evidence of the growing recreational 
use of ketamine in the UK has been provided by others 
(Measham et   al., 2001; Moore, 2004; Copeland and Dillon, 
2005; Moore and Measham, 2008). 
 France is another country where ketamine use 
appears to be significant. As detailed in the 2010 France 
National Report to the European Monitoring Centre 
for Drugs and Drug Dependence (EMCDDA 2010c), the 
Centres d ’ Accueil et d ’ Accompagnement  à la R é duc-
tion des Risques pour Usagers de Drogues (CAARUD) 
found that among the most striking changes in drug use 
and method of use there in the years 2008 – 2009 was 
the spreading of ketamine misuse outside the alterna-
tive party scene (see below). More than 7% of addicts 
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referred to the CAARUDs reported recent use of keta-
mine (approx. 5% reported daily use). In the general 
population of 17 year-olds, ketamine use was estimated 
at 0.6% (0.8% in males and 0.4% females). Furthermore, 
according to the same report, although in previous years 
the first encounter with ketamine was almost a chance 
event, this drug is now actively desired and sought out 
by new users. That is, ketamine is in the process of 
becoming a  ‘ first experimentation ’ substance for some 
individuals. 
 An increase in the recreational use of ketamine 
has been observed in other European countries as well 
(EMCDDA, 2011). Eight out of the 29 EMCDDA participat-
ing countries provided some information about ketamine 
use (in addition to the UK and France: Czech Republic, 
Denmark, Hungary, Ireland, Italy, and the Netherlands). 
The 2010 Czech Republic National Report to the EMCDDA 
(EMCDDA, 2010b), for example, included data from the 
2009 Safer Party Tour project (which provided preven-
tive and harm reduction services at 14 summer festivals) 
indicating that the lifetime use of ketamine among Safer 
Party affiliates was 10.8%. Similar data were contained 
in the 2010 The Netherlands National Report to the 
EMCDDA (EMCDDA, 2010d), which indicated an 8.5% 
prevalence of ketamine use among participants in large 
scale parties (raves) and 4.1% among visitors of clubs and 
discotheques. 
 However, the quality of the reports from the differ-
ent participating countries was not homogeneous, and it 
is not easy to understand to what extent the lack of data 
in a report reflects little or negligible ketamine abuse or 
simply a lack of reliable information. For example, the 
2010 Austria National Report to the EMCDDA (EMCDDA, 
2010a) makes no mention of ketamine, but the 2007 
report (EMCDDA, 2007) details the findings of a survey 
carried out on the spot at free techno and Goa-like events, 
according to which 23% of all participants used ketamine 
(Baumgartner, 2007). This was also the case for the reports 
of other countries. 
 Demographics of ketamine abuse 
 The large majority of ketamine users have a significant 
history of polydrug use, often confined to parties, more 
rarely as part of daily use activity. Generally, the first use 
of ketamine occurs in a group at a rave. Indeed, all avail-
able evidence shows that ketamine abuse is, at least ini-
tially, framed within the context of rave parties. Raves are 
parties with loud, electronic  ‘ techno-rock ’ music, laser 
light shows and all-night dancing held in clandestine 
locations, including warehouses, nightclubs and farm 
fields (Weir, 2000). They first became popular in the UK 
and the USA in the late 1980s and have since spread to 
other countries. 
 Many of the early ketamine users were jobless and 
without a fixed residence, their lifestyles being focused 
mainly on drug consumption and on the organization of 
raves. More recently, ketamine use has moved beyond the 
context of raves and has become popular in youth clubs 
whose clients have been in contact with the rave culture. 
In parallel with the spread of ketamine to mainstream 
discos and clubs, the social profile of users has become 
less marginal. 
 Reynaud-Maurupt et al. (2007a) argue that, among 
ketamine users, four  ‘ affinity groups ’ can be identified on 
the basis of distinct socio-demographic profiles and dif-
ferent levels of consumption:  ‘ alternative ’ ,  ‘ urban ’ ,  ‘ club-
bing ’ and  ‘ selected ’ . 
 The ‘alternative’ group is composed by counterculture 
enthusiasts with a hedonistic tinge. The setting of keta-
mine taking is represented by rave and free parties. It has 
been argued that this group can be further subdivided 
into Ravers and Travellers. Ravers come from the rave and 
 ‘ teknival ’ culture. They consume ketamine by sniffing and 
are socially functional. The Travellers ’ lifestyle focuses on 
drug consumption and parties. They live in unstable con-
ditions and frequently experience problems derived from 
drug consumption. Travellers often inject ketamine. 
 The ‘urban party’ group is music-oriented, and its 
habitat is represented by live music bars. Individuals in 
this group are well integrated at a social level and are char-
acterized first and foremost by their fondness for music. 
This group includes the highest percentage of students. 
 The ‘clubbing’ group is composed by hedonists who 
devote a substantial portion of their budget to partying 
and buying clothes. Their habitat is represented by clubs 
playing electronic music. The  ‘ gay friendly ’ establishment 
belongs to this particular affinity group. 
 The ‘selected’ group is composed by individuals who 
attend invitation-only or sponsored-entry bars or clubs 
requiring  ‘smart dress’ attires. The standards of living of 
these users are quite high, and there is very little overlap 
with the other groups. The selected group frequents loca-
tions usually accessed through coopting and cultivates a 
chic and hip image. 
 Finally, a particular population of ketamine users 
is represented by the  ‘ psychonauts ’ . The term psycho-
nautics is of recent coinage and has entered scholarly lit-
erature even more recently (e.g., Ott, 2001). Psychonauts 
may consume ketamine and other psychedelic drugs 
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( ‘ entheogens ’ ), to induce an altered state of conscious-
ness, thereby facilitating the  ‘ exploration ’ of the psyche. 
As their main goal is introspection, psychonauts use 
ketamine in quiet places and usually by injection. Pres-
ently, psychonauts represent a minority of ketamine 
users (Newcombe, 2008). 
 The setting of ketamine use 
 Environment plays an important role in modulating indi-
vidual responsiveness to addictive drugs (Caprioli et    al., 
2007a; Badiani et    al., 2011). For example, adverse life 
experiences (e.g., sexual abuse/harassment, combat-
stress, occupational stress and other forms of social and 
physical stress) can facilitate the initiation and the devel-
opment of drug abuse and then of drug addiction and, by 
acting acutely, can precipitate drug seeking after a period 
of abstinence (Aro, 1981; Triffleman et   al., 1995; Richman 
et   al., 1996; Brady et   al., 2001; Clark et   al., 2001; Price et   al., 
2004; Ompad et   al., 2005; Brown et   al., 2006; Reed et   al., 
2006). Another way the environment can affect drug 
taking is represented by drug-associated cues that can 
trigger drug seeking even after prolonged abstinence 
(Childress et al., 1984, 1986). 
 Also in the case of ketamine abuse, context appears 
to play a major role. As discussed above, ketamine abuse 
is, in fact, prevalent among individuals participating 
in music and dance events at nightclubs or rave parties 
(Curran and Morgan, 2000; Joe Laidler, 2005; Degenhardt 
and Dunn, 2008). This anecdotal evidence has recently 
received support from animal and human studies, which 
will be reviewed below, along with unpublished data that 
will be presented here for the first time. 
 Setting of ketamine use: 
pre-clinical studies 
 Preclinical research concerning the role of context in drug 
addiction has focused mostly on the ability of environ-
mental stimuli to act as stressors or as drug cues. However, 
context has been shown to affect drug taking in ways that 
are not easily attributable to stress or conditioning. For 
example, the presence of novel objects has been found to 
reduce the intake of amphetamine (Klebaur et   al., 2001), 
and high temperatures can increase the intake of 3,4-meth-
ylenedioxymethamphetamine (Cornish et   al., 2003). Even 
nonphysical, apparently negligible differences in the 
setting can powerfully alter drug-taking behavior, as indi-
cated by a series of studies in which rats were trained to 
self-administer heroin or cocaine under two deceptively 
similar environmental conditions. Some rats were trans-
ferred to the self-administration chambers immediately 
before the experimental sessions (non-resident rats), a 
procedure commonly used in most self-administration 
studies. Other rats were kept in the self-administration 
chambers at all times (resident rats). Thus, the physical 
characteristics of the self-administration environment for 
resident vs. non-resident rats were virtually identical, 
all differences being purely a function of familiarity. As 
illustrated in the top panels of  Figure 1 , we found that 
psychostimulant drugs, such as cocaine and ampheta-
mine, were self-administered more by non-resident rats 
than by resident rats, whereas the opposite occurred with 
heroin self-administration (Caprioli et    al., 2007b, 2008; 
Celentano et    al., 2009). The influence of setting on drug 
taking was particularly striking in experiments in which 
rats with double-lumen catheters were repeatedly given 
the opportunity to choose between two drugs within the 
same session (Caprioli et    al., 2009). In fact, most non-
resident rats chose cocaine over heroin, whereas resident 
rats tended to prefer heroin. 
 We have hypothesized that the setting may affect drug 
taking by providing an ecological backdrop against which 
drug effects are appraised as more or less  ‘ adaptive ’ (Cap-
rioli et   al., 2009; Badiani et   al., 2011). Briefly, we proposed 
that the sedative, inward-looking effects of heroin would 
be experienced as suitable to a safe, non-challenging 
home environment, whereas the sympathomimetic, acti-
vating, performance-enhancing effects of cocaine would 
be more appropriate to arousing, exciting contexts (this 
hypothesis will be discussed in more detail at the end of 
this review). On the basis of this initial hypothesis, we 
speculated that drugs producing effects somewhat similar 
to those of psychostimulants or opiates would also inter-
act with the environment in a similar manner. Indeed, 
we found that ethanol, which, at least at certain doses, 
depresses the central nervous system similar to opiates, 
was ingested in greater amounts by resident rats than by 
non-resident rats (Testa et   al., 2011). 
 Most important, we also predicted that the intrave-
nous self-administration of ketamine (first reported by 
Collins et   al., 1984) would be greater in non-resident rats 
than in resident rats. The effects of ketamine are particu-
larly complex, also in relation to the dose, and include, 
in addition to  ‘ dissociative ’ anesthesia: tachycardia, 
increased blood pressure, ataxia, hyper-excitability, agita-
tion, acute psychotic episodes, unpleasant vivid dreams, 
hallucinations and impaired cognitive function. However, 
Brought to you by | Universita degli Studi di Roma La Sapienza Biblioteca Alessandrina
Authenticated | aldo.badiani@uniroma1.it author's copy
Download Date | 11/6/13 8:56 AM
774      M.T. De Luca et al.: The setting of ketamine abuse
clubs or rave parties (Curran and Morgan, 2000; Joe 
Laidler, 2005; Degenhardt and Dunn, 2008) also leads us 
to predict greater preference for ketamine in non-resident 
than in resident rats. 
 Consistent with our hypothesis, we found that keta-
mine intake was much greater in non-resident rats than 
in resident rats (De Luca and Badiani, 2011). The bottom 
left-hand panel of  Figure 1 illustrates the dose-response 
curve for ketamine self-administration. Non-resident 
rats acquired ketamine self-administration at all training 
doses, whereas resident rats self-administered only the 
highest dose of ketamine (500  μ g/kg), but still four times 
less than non-resident rats (De Luca and Badiani, 2011). 
 The role of setting in ketamine (Parke-Davis, Detroit, 
MI, USA) self-administration is also indicated by the 
results of an experiment in which rats were given the 
opportunity to choose between ketamine and heroin 
(S.A.L.A.R.S., Como, Italy) within the same session. These 
findings are reported here for the first time. The experimen-
tal procedures were similar to those described by Caprioli 
et al. (2009). Briefly, 14 male Sprague-Dawley rats (Harlan, 
Italy), weighing 250 – 275    g at their arrival, were housed 
and tested in the same dedicated temperature and humid-
ity-controlled rooms, with free access (except during the 
test sessions) to food and water under a 14-h dark/10-h 
light cycle (lights off at 7:00 am). After the surgery, the 
rats were housed individually. All procedures were in 
accordance with the Italian Law on Animal Research 
(DLGS 116/92) and with the guidelines for the care and 
use of laboratory animals issued by the Italian Ministry 
of Health. Using standard surgical procedures, the rats 
received double-lumen catheters connected with cannu-
las secured to the rat ’ s skull, as described by Caprioli et 
al. (2009). At the end of the experiments, all rats under-
went a catheter patency test in which they received two 
i.v. boluses of 40   mg/kg of thiopental sodium (Pharmacia 
Italia, Milan, Italy), one in each catheter, with a 15-min 
interval between the two. No rat failed the test, that is, all 
rats became ataxic within 5 s after thiopental. The testing 
apparatus (ESATEL S.r.l., Rome, Italy), described in detail 
in previous papers (Caprioli et    al., 2009), consisted of 
self-administration chambers placed within sound- and 
light-attenuating cubicles and equipped with two retract-
able levers, two light cues positioned above each lever 
and a counterbalanced arm holding a liquid swivel. 
Each lever was connected via an electronic interface to a 
syringe pump (Razel Scientific Instruments, St. Albans, 
VT, USA). Personal computers controlled the chambers, 
via Programmable Logic Controller (Allen Bradley, Mil-
waukee, WI, USA), using control software developed by 
Aries Sistemi S.r.l. (Rome, Italy). 
 Figure   1   Drug taking as a function of setting in rats. 
This figure is based on previously published data (Caprioli et   al., 
2007b for cocaine; Caprioli et   al., 2008 for heroin; De Luca et   al., 2011 
for ketamine) and illustrates the mean ( ± SEM) number of infusions on 
the last day of the training phase (FR5 schedule of reinforcement) as a 
function of the setting. The data for each infusion dose were obtained 
in independent groups of rats (n = 11 – 15 for cocaine; n = 12 – 16 for 
heroin; n = 6 – 10 for ketamine). Resident rats were housed in the 
self-administration chambers. Non-resident rats were transferred 
to these chambers only for the test sessions (3   h each). Asterisks 
indicate significant differences (* p < 0.05; ** p < 0.01, **** p < 0.0001) 
between resident and non-resident groups. For details of the 
statistical analyses, see the original publications. 
at the doses used for recreational purposes, some, but by 
no means all, of the physiological, behavioral and sub-
jective effects produced by ketamine are similar to those 
produced by psychostimulant drugs, e.g., tachycardia, 
increased blood pressure, hyper-excitability and agita-
tion. Thus, it was reasonable to assume that these effects 
would be experienced as more appropriate to (or less 
aversive in) a non-home vs. a home environment, as pre-
viously reported for cocaine and amphetamine (Caprioli 
et    al., 2007a,b, 2008). (More difficult to speculate on is 
how the setting affected the appraisal of other effects of 
ketamine, such as hallucinations and ataxia.) 
 There is a partial overlap between ketamine and 
psychostimulants also with regard to the mechanisms of 
action, as ketamine has been reported to increase dopa-
mine efflux and reduce dopamine uptake in the nucleus 
accumbens (Hancock and Stamford, 1999). Finally, the 
fact that ketamine abuse in humans is associated with 
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 During the training phase, the rats were assigned to 
one of two conditions: resident and non-resident. Resident 
rats were housed in the self-administration chambers, 
where they remained for the entire duration of the experi-
ment. Non-resident rats (n = 8) were housed in standard 
cages and were transferred to the self- administration 
chambers immediately before the start of each testing 
session. 
 Resident rats (n = 6) were connected, through liquid 
swivels, to the infusion lines 3    h before the start of each 
session. During the 60 s preceding the start of each session, 
food and water were removed from the chambers, and the 
infusion pumps were activated so as to fill the catheters 
with the drug solution. Immediately before the start of 
each session, non-resident rats were transferred to the 
self-administration chambers, and their catheters were 
connected to the infusion lines. At the end of each session, 
food and water were given back to the resident rats and 
non-resident rats were returned to their home cages. The 
rats were trained for 10 consecutive daily 3-h sessions to 
self-administer ketamine (250  μ g/kg/infusion). Ketamine 
was alternatively paired with one or the other of the two 
levers, according to a counterbalanced design. That is, for 
some rats, ketamine was paired with the left lever on ses-
sions 1, 3, 5, 7 and 9, whereas pressing on the right lever 
had no programmed consequences; the opposite occurred 
on sessions 2, 4, 6, 8 and 10. For other rats, the sequence 
was inverted. After each infusion, the cue light was turned 
off, and the lever retracted. The cue light was turned on 
and the lever extended again after a time-out (TO) period. 
Both the fixed ratio (FR, i.e., number of consecutive lever 
presses required to obtain a single infusion) and the TO 
period progressively changed during training, to habitu-
ate the rats to obtain an infusion every 10    min. The FR 
increased from FR1 (sessions 1 – 2, with a 40-s TO, and ses-
sions 3 – 4, with a 60-s TO), to FR2 (sessions 5 – 6, with a 
2-min TO, and sessions 7 – 8, with a 3-min TO), and finally 
to FR5 (sessions 9 – 10, with a 5-min TO, and sessions 11 – 12, 
with a 10-min TO). The goal was to reach, by the end of 
the training phase, the same reinforcement schedule used 
during the subsequent choice phase. 
 During the choice sessions, some rats were given the 
opportunity to choose between ketamine and heroin, 
each paired with one of the two levers. Other rats instead 
received ketamine regardless of the chosen lever (that is, 
the  ‘ choice ’ was between ketamine and ketamine). Both 
levers were available simultaneously at time 0    min and 
then again 10   min after each infusion. The doses of keta-
mine and heroin were progressively increased during 12 
choice sessions (3-h each). During sessions 1 – 4, rats had 
a choice between 250  μ g/kg ketamine and either 25  μ g/kg 
heroin or 250  μ g/kg ketamine. During sessions 5 – 8, rats 
had a choice between 500  μ g/kg ketamine and either 
50  μ g/kg heroin or 500  μ g/kg ketamine. During sessions 
9 – 12, rats had a choice between 1000  μ g/kg ketamine 
and either 100  μ g/kg heroin or 1000  μ g/kg ketamine. At 
the end of the experiments, all rats underwent a catheter 
patency test using thiopental, as described above. 
 The following is a synopsis of the environmental 
conditions of resident and non-resident rats: 1) the self-
administration environment was physically identical 
for all rats, but for some animals this was also the home 
environment (resident group), whereas for other animals 
it represented a distinct non-home environment (non-
resident group); 2) immediately before the start of each 
session, the resident rats were briefly handled to remove 
food and water from the chamber; 3) during testing, the 
self-administration chambers contained no food or water; 
4) the distance traveled by the non-resident rats during 
the transfer to the self-administration chamber was about 
1   m (that is, all animals were kept in the same dedicated 
testing room for the entire duration of the experiments, 
and therefore there was no transport from one room to 
another); and 5) all other husbandry routines were identi-
cal in the two groups. 
 In summary, the differences in setting between resi-
dent and non-resident rats were of a purely  ‘ psychologi-
cal ’ nature. Yet, these apparently negligible differences 
were capable of altering drug preferences in a substantial 
manner. 
 During training, resident rats took much less keta-
mine than non-resident rats (data not shown), in agree-
ment with the findings by De Luca et al. (2011). Further-
more, when, during the choice phase, resident rats had 
access to ketamine on both levers, they took very little of it, 
regardless of the infusion dose, whereas non-resident rats 
worked for ketamine on both levers, in a dose-dependent 
manner ( Figure 2 ). An analysis of variance (ANOVA) limited 
to ketamine intake indicated, in fact, a significant effect 
of setting [F(1,13) = 6.53,  p = 0.024] and a significant setting 
× dose interaction [F(2,26) = 9.47,  p < 0.001]. In contrast, 
when resident rats had the opportunity to choose between 
ketamine and heroin, they eagerly took heroin, but not ket-
amine, following a dose-dependent pattern. The ANOVA 
yielded a significant effect of drug [F(1,2) = 6.75,  p = 0.016] 
and a drug × dose interaction [F(2,4) = 22.93,  p = 0.006]. This 
indicates that the lower propensity of resident rats to self-
administer ketamine was drug-specific and did not reflect 
a general inability to acquire drug-reinforced instrumen-
tal behavior. In contrast, non-resident rats that were given 
the choice between ketamine and heroin took, overall, 
about the same amount of the two drugs [F(1,3) = 0.42, 
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 p = 0.56], although, at the two highest doses, non-resident 
took about 60% (K50 vs. H500) and 35% (K100 vs. H1000) 
more ketamine than heroin. We investigated here a very 
limited combination of drug doses. It is quite possible that 
at certain doses (e.g., 50  μ g/kg of ketamine vs. and 1000 
 μ g/kg of heroin). Non-resident rats would have expressed 
a more robust preference for ketamine over heroin. Notice, 
however, that the most remarkable aspect of the present 
results (as well as of those reported in our previous 
papers) does not lie with the drug preferences of resident 
rats per se or non-resident rats per se, but with the com-
parison between the two groups, as this comparison indi-
cates that the reinforcing effect of a given dose of a given 
drug changes as a function of the  ‘ psychological ’ setting 
in which the drug is taken. 
 Setting of ketamine use: clinical 
studies 
 The fact that certain settings were able to modulate in 
opposite directions cocaine (or amphetamine or keta-
mine) vs. heroin self-administration in rats (Caprioli et   al., 
 Figure   2   Drug preferences as a function of setting in rats. 
This figure illustrates the mean ( ± SEM) number of drug infusions 
in resident (n = 6) vs. non-resident (n = 8) rats with double-lumen 
catheters that were repeatedly given the choice between two drug 
rewards. For some rats, the choice was between identical doses 
of ketamine (left-hand panels). Other rats had a choice between 
ketamine and heroin. Asterisks indicate significant differences 
(* p < 0.05) between heroin and ketamine. For details of the 
statistical analyses, see the text. 
2007b, 2008, 2009; Celentano et    al., 2009) indicated an 
unforeseen dissociation in the reinforcing effects of dif-
ferent classes of addictive drugs, which is not compatible 
with unitary models of drug reward (for an in-depth dis-
cussion of this issue, see Badiani et   al., 2011). 
 The heuristic relevance of these animal findings is 
indicated by the results of translational studies in which 
we investigated the setting of drug taking in human 
addicts (n = 79) who co-abused heroin and cocaine (Cap-
rioli et    al., 2009). As illustrated in  Figure 3 , the majority 
of addicts reported using heroin always or mostly at home 
and cocaine always or mostly outside the home. Partici-
pants were cocaine and heroin addicts recruited among 
the out-patients of an addiction clinic (Villa Maraini, 
Rome, Italy) who: 1) met the DSM-IVR drug dependence 
criteria for cocaine and/or heroin; 2) reported using 
heroin and/or cocaine [either drug for the Retrospective 
Reports study, both drugs for the Momentary Ecologi-
cal Assessment (EMA) study] at least once a week over 
the past 3 months; 3) did not meet the DSM-IVR criteria 
for schizophrenia or any other DSM-IV psychotic disor-
der, history of bipolar disorder or current major depres-
sive disorder; 4) were not under treatment with antipsy-
chotic medications; 5) did not have cognitive impairment 
severe enough to preclude informed consent or valid 
self-reporting; 6) did not have other medical conditions 
that would compromise participation in the study; and 7) 
had a fixed address. Approximately 74% of participants 
reported injecting heroin exclusively, or mostly, at home, 
whereas approximately 22% preferred to take it exclu-
sively, or mostly, outside the home. The opposite was true 
for cocaine. A small number of subjects did not express 
a clear preference for home vs. non-home environments 
(these individuals were indicated as  “ 50/50 ” in  Figure 3 ). 
Virtually identical results were obtained when the analy-
sis was limited to individuals who took both drugs either 
intravenously or intranasally, indicating that the choice of 
the setting was not driven by the route of drug taking. We 
have recently confirmed these results in a study using the 
EMA technique (Spagnolo et   al., 2011). 
 We used a similar approach to investigate the setting 
of ketamine use in humans. Preliminary data from this 
study (n = 19) are reported here. In agreement with the find-
ings obtained in rodents, most ketamine users reported 
taking the drug outside the home rather than at home 
( Figure 3 , right-hand panel). The specific non-home set-
tings of ketamine use were: parties (100%), raves (40%), 
Goa-like parties (30%), friends ’ place (30%) and rave fes-
tivals (20%). (Notice that each subject could indicate more 
than one setting.) In the process of conducting this study, 
we became aware of two previous papers reporting similar 
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findings. Dillon et al. reported that home was the preferred 
setting of ketamine use in 16% of cases, vs. 47% at dance 
and rave parties, 26% at clubs, 10% at the homes of friends 
and 1% at pubs (Dillon et    al., 2001, 2003). Reynaud-
Maurupt et al. (2007b) also investigated the circumstances 
of ketamine use and found that the last dose was taken 
in private home settings in 35% of cases (notice that this 
survey did not distinguish between the homes of users and 
the homes of their friends) vs. non-home environments in 
65% of cases (23% at free parties, 14% at techno festivals, 
6% at squat parties, 5% at rave parties and 5% in clubs). 
 Conclusions 
 We have previously hypothesized that environment influ-
ences the reward effects of drugs as a result of the appraisal 
of drug effects in relation to the surrounding stimuli (Cap-
rioli et   al., 2009; Badiani et   al., 2011). Each addictive drug 
produces a distinctive constellation of desired and unde-
sired effects, which may or may not partly overlap with 
those of other drugs. Some of these effects may be largely 
indifferent to an environmental context, whereas other 
effects would be more appropriate (or less inappropriate) 
in certain settings. The activating, performance-enhancing 
effects of cocaine and amphetamine, for example, would be 
experienced as more suitable to an exciting, relatively novel 
environment than to a home environment. In contrast, the 
sedative, inward-looking effects of heroin would be expe-
rienced as more appropriate to a safe, non-challenging 
home environment. That is, we hypothesize that the setting 
might affect drug choice by providing an ecological back-
drop against which drug effects are appraised as more or 
less  ‘ adaptive ’ . It is important to emphasize that emotional 
appraisal does not necessarily entail the conscious evalu-
ation of stimuli (see, for example, LeDoux, 1996, 2012). 
Thus, the fact that heroin is preferentially taken at home 
should not be seen as a mere expression of an intentional 
decision to take a  ‘ downer ’ where you can  ‘ slouch on the 
sofa ’ . It would be difficult to envisage such a mental process 
in the case of our resident rats, not only because attribut-
ing conscious planning to rats would be questionable at 
best. Indeed, resident rats did not have a choice between 
different settings but simply adapted their behavior to the 
context by taking less cocaine (or amphetamine or keta-
mine) and more heroin relative to non-resident rats. 
 As previously discussed, one of the reasons for pre-
dicting that the self-administration of ketamine, like 
that of cocaine and amphetamine, would be facilitated 
in non-resident rats relative to resident rats, was based 
on the existence of some similarities in the behavioral, 
physiological and neurochemical effects of ketamine and 
psychostimulant drugs. Of course, another major reason 
for predicting greater preference for ketamine in non-
resident than in resident rats was the anecdotal evidence 
that ketamine abuse in humans is associated with clubs 
or rave parties (Curran and Morgan, 2000; Joe Laidler, 
2005; Degenhardt and Dunn, 2008). Remarkably, the find-
ings of human studies (in addition to the data presented 
here, see Dillon et   al., 2001 and Reynaud-Maurupt et   al., 
2007a) coincided very closely with the results obtained in 
the rat. In our study, only a minority of users (about 10%) 
reported using ketamine exclusively, or mostly, at home. 
These users probably correspond to the  ‘ psychonauts’, 
who are known to titrate the dose to produce an internal 
state that is not compatible with social gatherings and 
requires instead quiet environments. 
 The clinical and pre-clinical findings reviewed here 































 Figure   3  Setting preferences for heroin, cocaine and ketamine use in humans, as indicated by retrospective reports. 
The data for cocaine and heroin use in addicts co-abusing the two substances (n = 79) were published previously (Caprioli et   al., 2009). 
The ketamine data (n = 19) are reported here for the first time. 
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for ketamine use. In particular, the study conducted in 
rats under controlled conditions indicate that the physi-
cal environment may affect ketamine reward at a very 
fundamental level, independent, at least in part, of social 
interactions. Furthermore, these and other findings (see, 
for example, Badiani et    al., 2011) challenge that notion 
that drug reward (and more in general reward  tout court ) 
represents a unified phenomenon, almost invariant of 
the specific psychopharmacological profile of the various 
drugs. Much can be learned about the neurobiological 
underpinning of drug reward by taking into considera-
tion the emotional appraisal of the specific effects pro-
duced by each drug within the context of the surrounding 
environment. 
 Received August 2, 2012; accepted October 7, 2012 
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